Central Denmark Region   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Viborg Denmark (2007)

Organization Overview

First Clinical Trial
2010
NCT01174186
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2025

Timeline

NOW
  • Now

Alternative names

Central Denmark Region

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Enterocolitis (Phase 4)

Heart Arrest (Phase 2)

Infarction (Phase 4)

Inflammation (Phase 4)

Myocardial Infarction (Phase 4)

Non-ST Elevated Myocardial Infarction (Phase 4)

Out-of-Hospital Cardiac Arrest (Phase 2)

Shoulder Impingement Syndrome (Phase 4)

Spondylarthritis (Phase 4)

Spondylitis (Phase 4)

Spondylitis, Ankylosing (Phase 4)

ST Elevation Myocardial Infarction (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 13